Lsl Pharma Group Inc. (LSL)
TSXV
0.3000
+0.0050 (+1.69%)
Closed
Oct 8, 2026
Day's Range
0.29500.3000
52 wk Range
0.27500.5600
Financial Statements - LSL - Lsl Pharma Group Inc.
Revenue
28.74M▲ 62.0%
Net Income
-2.82M▼ 185.0%Net Margin -9.8%
EBITDA
-52.00K▼ 103.0%
Free Cash Flow
-7.40M▼ 26.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|
| Sales | 28.74M | 17.74M | 10.02M | 8.21M | 8.77M | 4.82M |
| Cost of Goods | 23.64M | 12.40M | 8.38M | 10.38M | 6.24M | 4.31M |
| Gross Profit | 5.10M | 5.34M | 1.64M | -2.17M | 2.52M | 507.58K |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -2.31M | 406K | -3.95M | -6.75M | -65.26K | 809.27K |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 2.33M | 4.86M | -2.76M | 81K | 141.32K | - |
| Pre Tax Income | -2.88M | 3.36M | -8.47M | -8.06M | -1.62M | 82.62K |
| Income Tax | -65K | 50K | - | - | 147.45K | -5.38K |
| Net Income | -2.82M | 3.31M | -8.47M | -8.06M | -1.77M | 88K |
| EPS Basic | -0.02 | 0.03 | -0.11 | -0.098046 | -0.013526 | 0.00067 |
| EPS Diluted | -0.02 | 0.03 | -0.11 | -0.098046 | -0.013526 | 0.00067 |
| Basic Shares Outstanding | 117.61M | 105.41M | 80.35M | 82.22M | 131.37M | 131.37M |
| Diluted Shares Outstanding | 117.61M | 105.41M | 80.35M | 82.22M | 131.37M | 131.37M |
| Ebit | -244K | 5.11M | -6.90M | -6.79M | -42.43K | 617.59K |
| Ebitda | -52K | 1.75M | -3.01M | -5.82M | 790.22K | 990.62K |
| Net Income Continuous Operations | -2.82M | 3.31M | -8.47M | -8.06M | -1.77M | 88K |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
